Immunotherapy
Creative Biolabs Unveils Advanced Bispecific Antibody Platform at Industry Conference
Creative Biolabs demonstrates cutting-edge bispecific antibody technology with potential to revolutionize cancer immunotherapy, showcasing customized development capabilities and innovative research approaches.
Calidi Biotherapeutics Advances Cancer Immunotherapy Platform, Reduces Quarterly Losses
Calidi Biotherapeutics has made significant progress in its oncology research, receiving FDA clearance for a stem cell-based immunotherapy and presenting promising data on its Redtail virotherapy platform while simultaneously reducing operational expenses.
Calidi Biotherapeutics Advances Cancer Treatment Platform with Innovative Immunotherapy Approach
Calidi Biotherapeutics has developed a novel systemic antitumor virotherapy platform that delivers an IL15 superagonist directly into tumor microenvironments, potentially revolutionizing metastatic cancer treatment by boosting immune response while minimizing systemic toxicity.
Creative Biolabs Advances Antibody Technologies to Revolutionize Cancer Treatment
Creative Biolabs is expanding its innovative antibody-related technologies, targeting critical advancements in cancer research and immunotherapy. The company's platforms aim to enhance drug delivery precision and improve therapeutic strategies for previously challenging medical conditions.
Portuguese Researchers Uncover Promising Immunotherapy Approach for Colorectal Cancer
A breakthrough discovery by Portuguese researchers reveals a new type of white blood cell with exceptional tumor identification capabilities, potentially revolutionizing colorectal cancer treatment through targeted immunotherapy.
Portuguese Researchers Uncover Promising White Blood Cell for Colorectal Cancer Immunotherapy
Researchers in Portugal have identified a novel white blood cell type with potent tumor cell identification capabilities, potentially revolutionizing immunotherapy approaches for colorectal cancer, the third most common cancer globally.